RESULTS & CASE STUDIES
Anonymized cases showing how independent clinical-development judgment changes direction, reduces risk and creates real options.
HOW TO READ THESE CASES
Each case snapshot is anonymized, but follows the same structure so you can quickly see what was at stake, what we did, and what changed.
01
The therapeutic area, development stage and key constraints.
02
The critical question leadership needed to resolve.
03
How we applied independent evidence and strategic judgment.
04
What changed — and what options it created next.
CASE FAMILIES
Explore anonymized cases across the mandate types we see most often.
Reassessing design, endpoints and populations to improve probability of success.
Evidence strategy in areas of high uncertainty and heterogeneous populations.
Development and regulatory strategy across geographies and health systems.
Independent review and re-prioritisation when programmes are off track.
Rebuilding evidence, narrative and stakeholder engagement.
Independent assessment to inform investment, partnering and portfolio decisions.
WHAT THE CASES TEND TO REVEAL
Across indications, geographies and development stages, we see recurring challenges. The difference is what happens when the right evidence question is asked.
Important decisions made on incomplete or misaligned evidence
Over-optimistic assumptions about effect size, population or timelines
Regulatory, payer and commercial perspectives not sufficiently integrated
Late recognition of feasibility, operational or geographic constraints
When the right evidence question is asked, options emerge and better decisions follow
REPRESENTATIVE ANONYMIZED CASE SNAPSHOTS
Four examples, anonymized, showing how evidence and judgment can change the course of a programme.
NEURODEGENERATION
Context: Early neurodegeneration programme with high biological uncertainty.
Challenge: Preserve Phase II/III decision value while aligning safety, biomarkers, population and endpoints.
Intervention: Integrated development logic, endpoint and biomarker strategy, plus cross-functional decision gates.
Result: Decision-grade path from early data to Phase II/III planning.
RARE DISEASE & COMPLEX CNS
Context: Rare disease / complex CNS pivotal programme.
Challenge: Build evidence that can survive regulatory, HTA, payer and operational scrutiny.
Intervention: Endpoint and estimand alignment, operational guardrails and integrated value logic.
Result: Submission-ready protocol package and payer-credible evidence narrative.
CNS · MULTI-COUNTRY
Context: Late-phase CNS programme with feasibility drift and vendor underperformance.
Challenge: Restore realistic country/site strategy, recruitment control and evidence integrity.
Intervention: Re-forecasted feasibility, rebuilt country/site strategy, reset vendor governance and RBQM.
Result: Enrollment stabilised and execution became more predictable and decision-oriented.
CAPITAL & PARTNERING
Context: Capital raise and partnering discussions requiring a diligence-ready development narrative.
Challenge: Integrate regulatory path, pivotal evidence, payer logic and competitive positioning.
Intervention: Evidence architecture, risk map, mitigation plan and aligned value-inflection narrative.
Result: Stronger diligence readiness and clearer explanation of risk, value and optionality.
CASE LIBRARY
Download a summary of our case library or request a relevant example for your specific situation.
A DECISION AHEAD?
Start a conversation about your decision and how independent evidence and judgment can help.
Copyright © 2026 Manolo Beelke & Partners. All rights reserved.
